Tocilizumab and Systemic Corticosteroids in the Management of Patients with COVID-19: A Systematic Review and Meta- Analysis

被引:15
作者
Alkofide, Hadeel [1 ]
Almohaizeie, Abdullah [2 ]
Almuhaini, Sara [3 ]
Alotaibi, Bashayer [3 ]
Alkharfy, Khalid M. [1 ]
机构
[1] King Saud Univ, Coll Pharm, Dept Clin Pharm, Riyadh, Saudi Arabia
[2] King Faisal Specialist Hosp & Res Ctr, Specialist Hosp & Res Ctr, Pharmaceut Care Div, Riyadh, Saudi Arabia
[3] King Saud Univ, Coll Pharm, Riyadh, Saudi Arabia
关键词
COVID-19; tocilizumab; systemic corticosteroid therapy; coronavirus; severe COVID-19; DRUGS; CARE;
D O I
10.1016/j.ijid.2021.07.021
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: To date, there is no effective treatment for the new coronavirus disease (COVID-19). We aimed to systematically review the literature on the association between the combination of tocilizumab (TCZ) and systemic corticosteroid therapy (SCT) on outcomes of COVID-19 patients. Methods: We searched MEDLINE, Cochrane Central, and preprints, for studies in which health outcomes were compared between adults with severe COVID-19 who received TCZ and SCT and those who received standard of care without TCZ. Record screening, data extraction, and risk of bias assessment were per -formed in duplicate. Random effect models were used when pooling crude numbers and adjusted effect estimates of study outcomes. Results: Our search identified seventeen studies. The pooled crude mortality rate was lower in the com-bination arm (relative risk, RR = 0.62, 95% confidence interval [CI] = 0.42 - 0.91; I 2 = 60%). The adjusted mortality rates were also lower in the combination arm (RR = 0.58, 95% CI = 0.42 - 0.81; I 2 = 71%). The rate of superinfections did not differ between the two interventions. Conclusions: The findings of this study show that combination of TCZ and SCT compared to SOC has lower mortality rates. There is an urgent need for well-designed randomized trials to assess the safety and efficacy of this combination in subjects with severe COVID-19. (c) 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页码:320 / 329
页数:10
相关论文
共 44 条
[41]   Changes in blood coagulation in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis [J].
Xiong Mi ;
Liang Xue ;
Wei You-Dong .
BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (06) :1050-1052
[42]   The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis [J].
Yang, Zhenwei ;
Liu, Jialong ;
Zhou, Yunjiao ;
Zhao, Xixian ;
Zhao, Qiu ;
Liu, Jing .
JOURNAL OF INFECTION, 2020, 81 (01) :E13-E20
[43]   Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study [J].
Yazici, Yusuf ;
Curtis, Jeffrey R. ;
Ince, Akgun ;
Baraf, Herbert ;
Malamet, Raymond L. ;
Teng, Lichen L. ;
Kavanaugh, Arthur .
ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (02) :198-205
[44]   What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes [J].
Zhang, J ;
Yu, KF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (19) :1690-1691